Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant

Rhea-AI Filing Summary

Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shapiro Aron

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 25,000 options Exercise price: $2.63 per share Vesting date: June 10, 2027 +3 more

6 metrics

Options granted 25,000 options Stock Option (right to buy) granted to director

Exercise price $2.63 per share Conversion or exercise price for Common Stock

Vesting date June 10, 2027 Options become fully exercisable on this date

Expiration date June 10, 2036 Unexercised options lapse after this date

Underlying shares 25,000 shares Underlying Common Stock tied to the option grant

Post-grant derivative holdings 25,000 options Total stock options held following transaction

Key Terms

Stock Option (right to buy), 2024 Equity Incentive Plan, exercise price, Common Stock

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: "2.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shapiro Aron

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.63	06/10/2026		A		25,000		06/10/2027(1)	06/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kiora Pharmaceuticals (KPRX) director Aron Shapiro report on this Form 4?

Aron Shapiro reported receiving a grant of 25,000 stock options for Kiora Pharmaceuticals Common Stock. These options were issued under the company’s 2024 Equity Incentive Plan as compensation, not through an open-market purchase or sale of existing shares.

What are the key terms of Aron Shapiro’s KPRX stock option grant?

The grant covers 25,000 stock options with an exercise price of $2.63 per share. The options relate to Kiora Pharmaceuticals Common Stock and were awarded with no cash paid upfront, reflecting a compensation-related award rather than a market transaction.

When do Aron Shapiro’s Kiora Pharmaceuticals options vest and become exercisable?

The options become fully exercisable on June 10, 2027. Until that vesting date, Shapiro cannot exercise them to buy Common Stock. This single vesting date structure means the full award becomes available at once rather than in installments.

When do the KPRX stock options granted to Aron Shapiro expire?

The stock options expire on June 10, 2036 if not exercised earlier. After this expiration date, any unexercised options will lapse and no longer allow purchase of Kiora Pharmaceuticals Common Stock at the $2.63 exercise price.

How many Kiora Pharmaceuticals options does Aron Shapiro hold after this Form 4 transaction?

Following this grant, Shapiro holds 25,000 stock options directly according to the filing. These options give him the right to buy an equal number of Kiora Pharmaceuticals Common Stock shares at $2.63 per share once they vest.

Was Aron Shapiro’s KPRX stock option grant made under a company equity plan?

Yes. The filing states the option grant was issued under Kiora Pharmaceuticals’ 2024 Equity Incentive Plan. Such plans are commonly used by companies to grant stock-based compensation to directors, executives, and employees to align incentives with shareholders.